The US Food and Drug Administration (FDA) Guidance
for Industry document ‘Container Closure Systems for
Packaging Human Drugs and Biologics’, addresses the review
and evaluation of packaging requirements. According to this
document, each new drug application (NDA) or abbreviated
new drug application (ANDA) should contain sufficient
information to demonstrate that a proposed container
closure system and its components are suitable for its
intended use. Last, but not least, Mike Ludlow, Technical
Study Manager, CMC Analytical Services at LGC, focuses on
product packaging and new drug development.
https://international-pharma.com/wp-content/uploads/2017/04/Ensuring.pdf